

Information about the proposed Board of Directors for AGM 2021



Anders Härfstrand

Born 1956

Chairman of the Board since May 2020

Member of the Board since September 2019

Member of the Remuneration Committee and Audit Committee

Other assignments

Chairman of Härfstrand Consulting AG and board member of Prothena Inc.

Previous experience

Director of Karolinska Development AB from 2017 to 2019 and as Chief Executive Officer of BBB Therapeutics BV from 2014 to 2015. Prior to that, he was President and Chief Executive Officer Europe of Makhteshim Agan Industries Ltd. (now ADAMA); President and Chief Executive Officer of Humabs BioMed SA; and Chief Executive Officer of Nitec Pharma AG (now Horizon Pharmaceuticals). He has also served in various executive roles at Serono, Pfizer and Pharmacia. He has a significant operational global experience of the pharmaceutical industry especially from the US, Japan and Europe.

Education

MD and Ph.D from Karolinska Institutet in Stockholm.

Independence

Independent in relation to the company and its executive management

Independent in relation to major shareholders of the company

Holdings of shares or other financial instruments in the company (including holdings of related persons)

30,000 shares



Hege Hellström

Born 1965

Member of the Board since September 2019

Member of the Audit Committee

Other assignments

Founder and manager of Belnor BVBA, a consultancy and investment company. She is also a non-executive Board member at Camurus AB (CAMX.ST), a Swedish biotech company, and Advicenne (Euronext: ADVIC), a French pharmaceutical company.

Previous experience

Hege worked at the biotechnology company Sobi from 2013 until 2018 and was president for EMENAR (Europe, Middle East, North Africa and Russia). Prior to that, she was globally responsible for the Cardiovascular business area within Sanofi, VP Renal Europe and Head of Regional Liaisons at Sanofi, VP Renal and Endocrine Europe at Genzyme and General Manager Benelux at Genzyme. Before Genzyme, she was 13 years at Baxter.

Education

Norge B.Sc., Medical Laboratory Scientist, 1985, Oslo Metropolitan University, Norway.

Independence

Independent in relation to the company and its executive management

Independent in relation to major shareholders of the company

Holdings of shares or other financial instruments in the company (including holdings of related persons)

-



Birgit Stattin Norinder

Born 1948

Member of the Board since May 2020

Chair of the Remuneration Committee

Other assignments

Member of the Board of AddLife AB, Hansa Biopharma AB and Jettesta AB.

Previous experience

Extensive experience from international pharmaceutical and biotechnology companies in Sweden, USA and United Kingdom. Amongst many positions she has served as CEO and Chairman of Profilix Ltd., Senior VP Worldwide Product Development, Pharmacia & Upjohn and Dir. Int. Reg. Affairs Division, Glaxo Group Research Ltd. Birgit has also held several board and chairman positions of European biotechnology companies.

Education

M.Sc in Pharmacy from Uppsala University.

Independence

Independent in relation to the company and its executive management

Independent in relation to major shareholders of the company

Holdings of shares or other financial instruments in the company (including holdings of related persons)

-



Peter Zonabend

Born 1980

Member of the Board since March 2019

Chair of the Audit Committee

Other assignments

CEO Arwidsro, board assignment within Arwidsro.

Previous experience

CEO of Victoria Investments Holding Ltd, 2010-2017, Law Firm Fylgia, Law Firm Björn Rosengren.
Board assignments within Hövding Sverige AB, HQ AB, TCER AB, CBD Solutions AB.

Education

LL.M from Stockholm University, EMLE from Université Paul Cézanne Aix-Marseille III, Bsc in Business and Economics from Stockholm University and DU EAED from Université Paul Cézanne Aix-Marseille III.

Independence

Independent in relation to the company and its executive management

Not independent in relation to major shareholders of the company

Holdings of shares or other financial instruments in the company (including holdings of related persons)

500,000 shares. Manages 79,917 shares by proxy.

Andrea Buscaglia

Born 1964

Other assignments

Chief Financial Officer (CFO) of Medicines for Malaria Venture (MMV).

Previous experience

Andrea Buscaglia has extensive financial experience from over 30 years working in senior roles in the biopharmaceutical, MedTech, investment banking and accounting sectors. He was CFO of the medical device and biopharmaceutical companies Endosense (now Abbott Laboratories) from 2009 until 2012 and Nitec Pharma (now Horizon Therapeutics) from 2007 until 2009, and was Vice President Corporate Development at Serono (now Merck KGaA) from 2000 until 2007. Prior to that, he worked for three investment banks, namely S.G Warburg & Co. Ltd. (now UBS), Deutsche Bank and Salomon Smith Barney (Citigroup).

Education

Degree in Business Administration from the University of Bocconi in Milan, Italy and a Diploma in Accountancy from the University of Genoa, Italy.

Independence

Independent in relation to the company and its executive management

Independent in relation to major shareholders of the company

Holdings of shares or other financial instruments in the company (including holdings of related persons)

-

Notes

The information above refers to the situation at the time of the notice of the AGM.